About Us

About us

DR. SATYA VADLAMANI

Dr. Satya Vadlamani Is The Chairperson And Managing Director Of Murali Krishna Pharma Pvt. Ltd. (Mkppl) – A Novel Drug Delivery Systems Company In Maharashtra, India. With Her Resolute Determination And Commitment To Succeed, She Has Revolutionised The Indian Pharma Landscape, Positively Impacting Countless Lives. Holding A Degree In Electrical And Electronics Engineering, Dr. Vadlamani Brings To The Table Almost 30 Years Of Invaluable Experience In Global Marketing Of Pharmaceutical Products. Her Visionary Leadership Has Propelled Mkppl To Unprecedented Heights, Making It One Of The Important Players In The Industry

THE BIG LEAP

Dr. Satya Vadlamani, hailing from the esteemed IIT Bombay campus, was raised in an environment of academic excellence. Her father, Dr. Challa R Sarma, an Emeritus Professor at IIT Bombay, and her mother, an Economics postgraduate, instilled in her a passion for education and excellence. Growing up amid academic excellence, she developed a strong desire to pursue engineering like her peers. She enrolled at the prestigious Gandhi Institute of Management (GITAM) in Visakhapatnam, where she embarked on her journey to become an accomplished professional. She recently achieved a significant milestone by obtaining a Ph.D. in Strategic Management from the Indian Management School and Research Centre, further enhancing her qualifications and expertise.

DYNAMIC ROLES

The leader began her professional career in 1992 in the area of marketing at Armour Chemicals Ltd., where she demonstrated her mettle and swiftly garnered recognition for her exceptional abilities. Subsequently, she ventured into a new professional chapter with Biochem Synergy Ltd., where her trajectory remained steadfastly upward. With each role she assumed, she exhibited a remarkable blend of expertise, earning accolades, and solidifying her reputation as a force to be reckoned with. She reached the pinnacle of her career, attaining the esteemed position of General Manager, International Marketing at Ajanta Pharma Ltd.

EXPANDING HORIZONS

It was 1997, when Dr. Vadlamani embarked on her entrepreneurial journey with the establishment of Murli Krishna Exports Pvt. Ltd. Initially functioning as an indenting operation, the company facilitated trade in pharmaceutical products. Sensing the potential for growth, in 2003, she transitioned the company from indenting to trading, a strategic move that proved instrumental in its expansion. Under her visionary leadership, Murli Krishna Exports flourished, specialising in the export of bulk Active Pharmaceutical Ingredients (APIs) and semi-finished formulations, specifically in pellet form. Leveraging her profound understanding of the pharmaceutical landscape, she identified an opportunity to further capitalise on the industry’s demands. In 2004, she ventured into a new endeavour, by establishing MKPPL–a 100% export- oriented unit. This innovative enterprise, commissioned in 2005, focused on the manufacturing of semi-finished formulations. Starting as a Regulatory Compliant prefinished formulation intermediates facility in 2004, the company evolved into a finished dosage firm specialising in FTF formulation. Initially, MKPPL focused on leveraging microencapsulation as a drug delivery system. However, the company constantly evolved and focused on innovation. Today, it has expanded its capabilities to encompass cutting-edge technologies such as nanoparticles and nano encapsulations. Its expertise extends to diverse therapeutic areas, including ophthalmology, corticosteroids, oncology, transdermal applications, and oral solid dosage products. The transformational journey showcases its relentless pursuit of progress. Dr. Vadlamani further highlights the company’s focus on research and development that has helped it amass a significant number of patents, underscoring its prowess in intellectual property. Moreover, its emphasis on aqueous-based technologies has further propelled its advancements. The entrepreneur envisions MKPPL as a formidable force in the domains of nanoparticles, niche developments, and niche delivery systems. She wants MKPPL to attain global recognition as a leading provider of innovative drug delivery systems. She emphasises that the organisation’s aim is to establish itself at the pinnacle of the field worldwide. Rather than competing with others, the focus is on surpassing its own achievements.